A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
{{output}}
Immunologically unresponsive tumours often resist immune checkpoint inhibitors due to the low abundance of tumour-specific T cells and an immunosuppressive microenvironment, despite pronounced infiltration of non-tumour-specific (bystander) T cells. Here we an... ...
